ClinicalTrials.Veeva

Menu

SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve

N

National Center for Cardiovascular Diseases

Status

Enrolling

Conditions

Coronary Artery Disease

Study type

Observational

Funder types

Other

Identifiers

NCT06030596
SPECT MBFQ Trial II

Details and patient eligibility

About

Recent evidences have demonstrated improved diagnostic accuracy for detecting coronary artery disease (CAD) when myocardial blood flow (MBF) is quantified in absolute terms using single photon emission tomography (SPECT) compared to conventional myocardial perfusion imaging (MPI). However, there are no uniformly accepted cutoff values of MBF and MFR derived from SPECT for diagnosing hemodynamically significant CAD. Particularly, the diagnostic performance for quantitative SPECT has not been validated using fractional flow reserve (FFR). The aim of this prospective study is to determine optimal cutoff values of absolute MBF and MFR derived from NaI (Tl)-based SPECT and to evaluate the diagnostic efficacy of this quantitative technology utilizing invasive coronary angiography (ICA) in combination with FFR results as the reference standard in patients with suspected or known CAD.

Enrollment

210 estimated patients

Sex

All

Ages

18 to 79 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 18 ~ 79 years old
  • At least one CAD risk factor
  • Intermediate to high pre-test likelihood for CAD
  • Suspected or known CAD, clinically referred for invasive coronary angiography
  • Able and willing to comply with the study procedures
  • Written informed consent

Exclusion criteria

  • History or risk of severe bradycardia
  • History of myocardial infarction, dilated cardiomyopathy, hypertrophic cardiomyopathy, valve issue or congenital heart disease
  • Wheezing asthma or COPD
  • Known second- or third-degree AV block
  • Known hypersensitivity to dipyridamole or adenosine
  • Known coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) prior to screening
  • Breastfeeding or pregnancy
  • Claustrophobia or inability to lie still in a supine position
  • Unwillingness or inability to provide informed consent

Trial design

210 participants in 1 patient group

coronary artery disease
Description:
Suspected or known coronary artery disease

Trial contacts and locations

1

Loading...

Central trial contact

Lei Wang, MD/PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems